SEP 20, 2020 3:30 PM PDT

New Drug Shows Promise in Treating Advanced COVID-19

WRITTEN BY: Annie Lennon

As the COVID-19 pandemic rages on, the search for drugs to combat the virus is ongoing. Now, scientists have found that a new drug, known as 4-Phenulbutiric acid (4-PBA), can modulate the body's inflammatory response to COVID-19 in animals. 

In the study, the authors note that the inflammatory process common in patients with severe cases of COVID-19 causes the release of cytokines- immune cells that then put the body's immune system into overdrive in what's known as a cytokine storm. Leading blood vessels to become extremely permeable, it often results in multiple organ failure and then death. As such, treating these cytokine storms is essential for managing the disease. 

Already, 4-PBA, under the name 'Buphenyl', is used as an anti-stress drug against other diseases that modulate cellular stress, including urea cycle disorders. As such, the researchers set out to see whether the drug could also be used to combat similar stress caused by COVID-19. 

From animal tests, the researchers confirmed that the treatment was able to 'fully curb mortality caused by respoirtory failure from cellular stress'. 

The researchers also managed to identify the endoplasmic reticulum resistant protein, 'Binding Immunoglobulin Protein' (BiP), a biomarker for cellular stress in the blood. They managed to do so by finding a correlation between high levels of the biomarker and inflammatory severity from COVID-19 infections. 

As such, the researchers say that BiP levels could both serve as an early indicator for how effective 4-BPA treatment may be, as well as to indicate groups at more risk of severe complications from COVID-19. 

"Therefore, if we know that the patient suffers from cellular stress, we can kill two birds with one stone - we can detect susceptibility before infection occurs and know how to treat it in due time," says co-author of the study, Ivan Duran, from the University of Malaga in Spain. 

 

Sources: Deccan HeraldFDA

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 14, 2022
Drug Discovery & Development
COVID-19 Drug Combo More Effective than Single Drugs
APR 14, 2022
COVID-19 Drug Combo More Effective than Single Drugs
COVID-19 is more effectively treated by a combination of drugs than singular drugs alone. The corresponding study was pu ...
APR 20, 2022
Health & Medicine
The Link between Mental Health and COVID Breakthrough Infection
APR 20, 2022
The Link between Mental Health and COVID Breakthrough Infection
Researchers from University of California San Francisco and the San Francisco Veterans Affairs Health Care System conduc ...
MAY 26, 2022
Cannabis Sciences
Cannabis Crystal Polymorphism
MAY 26, 2022
Cannabis Crystal Polymorphism
A new published commentary in the Journal of Cannabis Research indicated that cannabis crystallinity may determine level ...
JUN 02, 2022
Cancer
Call to Diversify Clinical Trials
JUN 02, 2022
Call to Diversify Clinical Trials
Clinical Trials represent an integral component of biomedical research.  These research studies utilize human subje ...
JUN 07, 2022
Health & Medicine
Drug that lowers blood sugar also reduces blood vessel dysfunction caused by aging
JUN 07, 2022
Drug that lowers blood sugar also reduces blood vessel dysfunction caused by aging
Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives ...
JUN 06, 2022
Drug Discovery & Development
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
JUN 06, 2022
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
Weight loss achieved via bariatric surgery among adults with obesity is linked to a lower risk of developing cancer and ...
Loading Comments...